Literature DB >> 7307442

Lymphomas of the testis-results of treatment 1960-77.

G Read.   

Abstract

Fifty-one patients with malignant lymphoma presenting in the testis are reported. The tumours were all diffuse non-Hodgkin's lymphoma. Eight patients had bilateral involvement. Fifty-three per cent of patients had evidence of spread beyond the testis at presentation and 75% at some time. The actuarial survival for all patients was 20% and for patients with disease apparently confined to the testis 40%. There was a survival advantage for patients with right sided tumours and lymphocytic histology. Chemotherapy using the VAP regime followed by radiotherapy to sites of bulky disease is recommended for patients with evidence of spread at presentation. For patients with disease apparently confined to the testis it is suggested that consideration should be given to adjuvant chemotherapy following radiotherapy to the abdominal nodes and scrotum.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7307442     DOI: 10.1016/s0009-9260(81)80340-6

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  4 in total

1.  Primary testicular and intraocular lymphomas: two case reports and a review of the literature.

Authors:  Dana J Wallace; Chandra R Altemare; De Fen Shen; Marc D deSmet; Ronald R Buggage; Robert B Nussenblatt; Chi-Chao Chan
Journal:  Surv Ophthalmol       Date:  2006 Jan-Feb       Impact factor: 6.048

2.  A case of bilateral testicular lymphoma.

Authors:  I Romics; S Fekete; M Bély; O Esik; B Szende
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

3.  Prospective study of follow up alone in stage I teratoma of the testis.

Authors:  G Read; R J Johnson; P M Wilkinson; B Eddleston
Journal:  Br Med J (Clin Res Ed)       Date:  1983-11-19

4.  Primary testicular lymphoma.

Authors:  Filiz Vural; Seckin Cagirgan; Guray Saydam; Mine Hekimgil; Nur Akad Soyer; Murat Tombuloglu
Journal:  J Natl Med Assoc       Date:  2007-11       Impact factor: 1.798

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.